ioneer

Phase A — Understand the business

Lens 1 · Company Overview

ioneer Ltd is an Australian-incorporated (North Sydney HQ; Reno, NV operating office) developer that is the operator and 100% owner of the Rhyolite Ridge Lithium-Boron Project in Esmeralda County, Nevada — "the only known lithium-boron deposit in North America and one of only two known such deposits in the world". It is dual-listed: ordinary shares on the ASX (INR), ADSs on Nasdaq (IONR, 1 ADS = 40 ordinary shares, BNY Mellon depositary). It is a foreign private issuer filing 20-F (not 10-K), reports under IFRS, and is an emerging-growth / non-accelerated filer. CIK 0001896084; commission file 001-41412.

The business model is binary and pre-commercial: there is no revenue and the company "has not yet commenced commercial production at any of [its] properties". The value proposition rests on one geological accident — Rhyolite Ridge contains both lithium and boron in the same searlesite ore, so boron (boric acid) is sold as a by-product credit that subsidises the cash cost of lithium. Management's repeated claim: "The Project's commercial viability is made possible by having both lithium and boron revenue streams" and "Boron remains one of the most stable natural resource commodities over many decades". Expected revenue mix: boric acid ~25% of Project revenue, lithium the balance.

Customers (offtake — the demand side is largely de-risked):

• Lithium (carbonate, tpa): EcoPro Innovation 7,000 (Korea; up from 2,000); Ford Motor Company 7,000; Prime Planet Energy & Solutions (PPES — Toyota/Panasonic JV) 4,000; Dragonfly Energy (DFLI) — variable surplus tonnes. The three binding deals "account for approximately 90% of our expected first three years of production of lithium carbonate".
• Boron (boric acid, tpa): Dalian Jinma 105,000 (China/Taiwan distribution); plus Kintamani Resources and Boron Bazar — together placing "100% of our first four years of projected boric acid production".

Contract structure: these are multi-year binding offtakes (3–5yr), not take-or-pay capacity commitments that pre-fund capex; they secure demand, not the build. The build is funded separately (see Lens 5). Key suppliers/partners on the delivery side: the DOE (lender), Goldman Sachs (financing advisor), and the prospective Korean consortium (KIND + Hyundai Engineering, LOI stage).

Lens 2 · Supply Chain

Map upstream → ioneer → end customer, named at every node:

• Upstream inputs (the real chokepoint is reagents, not ore): Rhyolite Ridge is a chemical operation, not just a dig — the flowsheet leaches searlesite ore with sulphuric acid produced on-site from a sulphuric-acid plant (which co-generates power). So the binding input dependencies are sulphur supply and the acid-plant / power island, plus water rights in arid Nevada (the 20-F lists water-rights payments as an ongoing pre-FID cost). Mining is conventional open-pit (low strip), so the orebody itself is not the bottleneck — recovery chemistry is.
• The asset: 100%-owned by ioneer Ltd; on public land administered by the BLM (Dept. of Interior) — fully permitted (Record of Decision Oct 2024).
• Processing / EPC: ~70% of advanced engineering complete; AACE Class 2 capital estimate. Prospective partner Hyundai Engineering would sit here (EPC + equity).
• Lithium downstream: Rhyolite Ridge produces lithium carbonate (technical and battery grade) → battery-materials converters/cell makers: EcoPro (Korea, cathode), PPES (Toyota/Panasonic), Ford (OEM), Dragonfly (US ESS). An R&D MOU with EcoPro covers lithium-hydroxide conversion (the "Lithium Clay R&D project," explicitly excluded from Stage 1 economics).
• Boron downstream: boric acid → industrial/agricultural/glass/electronics buyers via Dalian Jinma (China/Taiwan distributor), Kintamani, Boron Bazar. Boron's incumbent supply is highly concentrated — Eti Maden (Turkey, ~60%) + Rio Tinto (~25%) = ~85% of the ~4.5 Mtpa global market, so ioneer would be a rare new Western boron source — a strategic, not just commercial, position.

Single-source dependency that defines the equity: there is exactly one asset. No diversification, no second project to cushion a permit, hydrology, or financing setback. The chain's true chokepoint is not geology or demand — it is capital (Lens 5).

Lens 3 · Competitive Advantages (moats)

The moat is the orebody, not the company — and it is genuinely unusual:

1. Co-product economics (the core edge). Because boron is co-located and sells at a stable price, the boric-acid credit pushes lithium-equivalent cash costs toward the bottom of the global cost curve. ioneer claims a "stable overall operating cost structure … due to the scale and reliability of its boric acid credit". A first-quartile cost position is the only durable moat in a commodity — it is what lets a mine survive trough prices that kill marginal peers. This is the single most important fact about the asset.
2. Scarcity + location. Only-known lithium-boron deposit in North America; one of two in the world. In a US-policy environment prizing domestic critical-minerals supply, a fully-permitted, shovel-ready, 100%-owned US lithium source is scarce optionality — reflected in the DOE's willingness to lend ~$1B.
3. Permitting moat (the highest barrier in US mining). Federal Record of Decision (Oct 2024) after a process that began early 2020, upheld by the US District Court on 2026-03-31. A permitted US mine is a multi-year, litigation-laden moat competitors cannot quickly replicate. (Caveat: a Ninth Circuit appeal is live — Lens 10/13.)
4. Long life. ~77-year mine life on the October 2025 reserve — optionality value far beyond a single price cycle.

Bargaining power: weak as a developer (it needs the partner/lender far more than they need it — see the Sibanye walk-away, Lens 5). Over boron customers it has more leverage (scarce Western supply); over lithium customers, little — lithium carbonate is a global commodity and offtakes are price-referenced. The moat protects the project's economics at trough prices; it does not protect shareholders from dilution while the gap is funded.

Lens 4 · Segments

No reported revenue segments — pre-revenue (segments.csv empty). The only economically meaningful "segment" split is the future revenue mix: lithium ~75% / boron ~25% of Project revenue. Geographically the asset is 100% Nevada/US; the corporate entity is Australian. The IFRS accounts treat the whole group as a single operating segment (the Managing Director is the chief operating decision-maker). The meaningful trend is on the resource/reserve, not revenue: mineral resource +45% to 510 Mt (Mar 2025); ore reserve more than quadrupled to ~247 Mt (Jun 2025), updated to a 265.5 Mt proven & probable reserve at October 2025 containing 2,039 kt LCE-equivalent / 7,761 kt boric-acid-equivalent (recovered 1,636 kt LCE / 5,447 kt H3BO3).

---

Phase B — Measure performance (reframed: project economics + funding, no earnings)

Lens 5 · "Earnings Result" → Project economics, balance sheet & the funding gap

There is no earnings print to analyse — so the equivalent question is "what are the economics, and can it fund the build?"

Project economics (October 2025 Technical Report — ``, from ioneer disclosure):

• After-tax levered NPV (8% real): ~US$2,299.9M; after-tax levered IRR: 23.2%.
• Mine life ~77 years, ~266 Mt mined/processed at ~3.4 Mtpa average.
• First-25-year production: ~24,500 tpa lithium carbonate equivalent + ~135,500 tpa boric acid.
• Average annual EBITDA: ~US$563.4M (Years 1–25); ~US$416.6M life-of-mine.
• Economics improved through 2025 via leach-retention-time reduction (3 days → 2 → 1.5), lifting production without proportional capex.

Capex & the gap (the number that matters most):

• Total capex to complete: US$1,683.2M (incl. 10% contingency) — more than double the 2020 DFS estimate of US$785M. Management explicitly warns of continued construction-cost inflation (labor, fuel, logistics) before FID.
• Funding stack: US$996M DOE loan (US$968M principal + US$28M capitalised interest, 20-yr term, US-Treasury-linked fixed rate) — undrawn, with conditions precedent including "closing a strategic partnering agreement for the equity component". So debt covers ~59% of capex; the remaining ~US$687M+ equity is not yet secured.
• The Sibanye hole: the original equity solution — Sibanye-Stillwater's US$490M for 50% of the JV — was terminated by Sibanye in Feb 2025 on lithium-price weakness ("did not meet … investment hurdle rates at prudent pricing assumptions"). That left the equity gap open; ioneer re-hired Goldman Sachs and is running a partnering process now skewing toward a consortium (Korean KIND + Hyundai Engineering LOIs) rather than a single 50% buyer.

Balance sheet (clean, tiny, dilutive — ``, 20-F as of 2025-12-31):

• Cash US$17.86M (down from US$25.06M Jun-2025, US$35.72M Jun-2024, US$52.71M Jun-2023 — a steady burn-down).
• Capitalised exploration & evaluation asset US$209.0M (the cumulative investment in Rhyolite Ridge).
• Total assets US$232.5M; total liabilities just US$2.3M (no borrowings drawn); net assets US$230.2M.
• Contributed equity US$309.5M vs accumulated losses US$74.0M — i.e. ~US$309M raised over the life of the company to build a US$209M asset and fund overhead.
• Operating losses are trivially small (the company capitalises project spend and expenses almost nothing): TY2025 (6-mo transition) loss US$4.07M; FY2025 US$9.55M; FY2024 US$7.83M; FY2023 US$6.39M. Zero income tax (loss-making).

Liquidity / going concern: Going concern is appropriate — but only after a February 2026 placement of 400M new shares for ~A$72M (~US$50M). Management states sufficient working capital "to support its operations up to April 30, 2027". That is a ~12-month runway to the binding-partner / FID decision — adequate, not comfortable.

Capital-structure dilution (the bear's quietest, strongest point): ordinary shares 2,674,633,957 (Dec-31-2025) → 3,033,113,645 (Mar-31-2026) after the Feb raise — +13% in one quarter. At ~3.03B ordinary shares ÷ 40 = ~75.8M ADS-equivalent; at ~US$4.68/ADS that is a market cap of ~US$355–374M.

Lens 6 · "Earnings Calls" → Management narrative / quarterly updates (sentiment trend)

No earnings calls (pre-revenue). The analogue is the quarterly activity reports (6-Ks) and the narrative arc, where the tone has shifted markedly:

• 2022 (peak): offtakes stacking up (Ford, PPES), DOE conditional commitment — confident "globally significant producer" framing.
• Feb 2025 (trough): Sibanye walks; tone turns to "pleased to resolve this pending matter," re-engaging Goldman, "commenced preparation for a strategic partnering process" — i.e. reframing a setback as clarity.
• 2025 (rebuild): three consecutive upward technical-report revisions (Jun → Sep → Oct), each "material improvement in project economics," plus the resource/reserve quadrupling — a deliberate cadence of de-risking the asset while the financing lagged.
• 2026 (cautious progress): District Court win (Mar 31), US$50M raise (Feb), and June 2026 Korean LOIs with explicit hedging — the LOIs are "non-binding … do not create legally enforceable obligations," next milestone is MOUs "expected in July 2026," with FID targeted 2H 2026 and first production 2029.

The recurring phrases: "fully permitted," "low-cost," "boron credit," "strategic partnering process," "subject to satisfaction of conditions precedent." The phrase they stopped saying: any firm FID date — it has slipped repeatedly (originally targeted years ago, then H1-2025 JV close, now 2H-2026). Sentiment read: persistently optimistic on the asset, persistently slipping on the money.

Lens 7 · Comps (developer peer set — NOT a P/E table)

A pre-revenue developer has no earnings multiples; the right frame is EV vs project NPV (a P/NAV proxy) and market cap vs the US-developer cohort. Multiples below are `` or n/a.

Read: ioneer trades at a steep discount to NPV (~0.15× P/NAV) and at ~¼ of Lithium Americas' market cap — the discount is the market pricing the financing/dilution/execution gap and the appeal risk, exactly as it should for a pre-FID single-asset developer that just lost its equity partner. The comp that matters: LAC closed its equity (GM) and is drawing its DOE loan; ioneer has done neither. The re-rate trigger is closing the gap LAC already closed. Do not fabricate a P/E or EV/EBITDA here — there are no earnings.

Lens 8 · Stock-Price Catalysts (what moves IONR/INR)

History shows the stock trades on two factors only — the lithium price cycle and project/financing milestones — not on financials (there are none):

• 2022 peak → 2024 trough: INR fell with the lithium price collapse from the 2022 high; "lithium prices have tumbled from a 2022 peak, deterring some investments" — down ~55% from start-2022 by late-2022 and weak thereafter.
• Oct 2024: Record of Decision (federal permit) — a major de-risking catalyst.
• Jan 2025: DOE loan upsized to US$996M (from the US$700M 2023 conditional commitment) — positive.
• Feb 2025: Sibanye terminates the JV — INR fell ~1.9% on the day to A$0.0407 (note: prices are in single-digit cents on the ASX line; the Nasdaq ADS ≈ 40× that), market cap ~A$344M (~US$217M).
• 2025: three upward economics revisions + reserve quadrupling — supportive.
• Mar 31, 2026: District Court upholds the permit — positive; Apr 9, 2026: plaintiffs appeal to Ninth Circuit — overhang.
• Jun 2026: Korean (KIND/Hyundai) LOIs — modest positive (non-binding).

Pattern: this is a high-beta call option on (a) the lithium price and (b) the binary financing close. The single biggest upcoming >5% catalyst is a binding strategic-partner/consortium agreement (the FID gate). A binding deal re-rates it; another walk-away or a Ninth Circuit reversal halves it.

---

Phase C — Judge people & books

Lens 9 · Management

• James D. Calaway (68) — Executive Chairman. The single most important person in the thesis. He was non-executive Chairman of Orocobre for ~8 years, taking it "from its earliest development to becoming a significant producer of lithium carbonate and a member of the ASX 300" — Orocobre later merged with Galaxy to form Allkem. He has actually built a lithium developer into a producer once before, and Orocobre was itself a lithium-with-boron asset (Olaroz/Borax Argentina) — so the co-product playbook is literally his prior. Also previously chaired Datacert (sold for US$310M). This is a genuine, relevant, quantified track record — the strongest qualitative asset besides the orebody. Appointed Chairman 2017, Executive Chairman Jul-2020.
• Bernard Rowe (58) — Managing Director & CEO since Aug-2007. Geologist; led the Nevada exploration that became Rhyolite Ridge (the predecessor Global Geoscience began Nevada work in 2003 under Rowe). Long tenure = deep asset knowledge but also the person who has run an 18-year pre-revenue developer. TY2025 total comp ~US$1.19M (82% "at risk").
• April Hashimoto — CFO. Ex-SVP Finance at Lithium Americas Corp — directly relevant project-finance/lithium experience; a Nov-2025 consulting agreement with her is the one disclosed related-party item.
• Matt Weaver — SVP Engineering & Operations (BHP/Rio Tinto/Newmont) — credible mine-build operator.
• Skin in the game: thin. Insiders as a group own only 5.72% (Rowe 2.60% / 78.8M shares via Mopti entities; Calaway 2.10% / 63.6M via Lithium Investors Americas LLC). No founder mega-stake. Largest holder is Centaurus Capital LP at 14.1% (a financial holder), with BNY Mellon 6.8% as depositary nominee.
• Capital-allocation history: the only allocation decision a pre-revenue developer makes is how it raises and spends — and the record is serial equity issuance (US$309.5M contributed equity; share count to ~3.03B). That is normal for the stage but it is the dilution machine the bear points at. To their credit: they secured offtakes, the permit, and a US$996M federal loan — and they walked from a bad partner price (or had Sibanye walk) rather than over-committing.
• Archetype: a promoter/developer team led by a proven lithium-developer chairman — exactly the profile you want to de-risk and sell or fund an asset, with the corresponding risk that the incentive is to keep the project alive (and raising) rather than to protect per-share value.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst on a pre-revenue IFRS developer, the income-statement/revenue-recognition risks that dominate operating-company forensics are largely absent (no revenue, no inventory, no receivables of consequence, US$1.7M payables). The real forensic surface is different:

1. Capitalised exploration & evaluation — US$209.0M sitting as a non-current asset. Under IFRS 6, E&E costs are capitalised, not expensed — which is why reported losses are tiny (US$4–10M/yr) despite ~US$200M deployed. This is the single most important accounting point: the income statement massively understates the economic burn. If the project's recoverable amount ever falls below carrying value (a financing failure, a permit reversal, a sustained lithium-price collapse), this US$209M is impaired in one stroke — wiping most of the US$230M net assets. The asset's carrying value is an impairment-test artifact, not a market value.
2. Going-concern dependence on continuous capital markets access. Runway only to Apr-30-2027; the entire build (US$1.68B) is unfunded as to equity. Not a red flag of fraud, but the structural fragility that defines the equity.
3. Stock-based comp / dilution — modest in P&L terms (equity compensation reserve small) but the share-count growth is the dilution vector, not opaque SBC.
4. Cash vs "earnings" divergence — moot here; cash burn is visible directly in the falling cash line (US$52.7M → US$17.9M over three years), the honest signal.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: None. No LR or AAER names ioneer in the search period 2021-06-30 → 2026-06-30.
• Non-SEC enforcement (FTC/DOJ/FDA/etc.): no material enforcement actions found.
• Item 3 Legal Proceedings (the live one): the material litigation is environmental, not financial — Center for Biological Diversity v. Stone-Manning (joined by Great Basin Resource Watch and the Western Shoshone Defense Project), challenging the BLM/USFWS approval over Tiehm's buckwheat, an ESA-listed wildflower whose entire known population sits in/around the project footprint. The US District Court for the District of Nevada upheld the approval on 2026-03-31; plaintiffs filed a Ninth Circuit appeal on 2026-04-09. ioneer states the appeal "is not expected to delay commencement of construction" and anticipates a Ninth Circuit decision mid-2027.
• Net: "No material regulatory or accounting-enforcement findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 20-F disclosure as of 2026-06-30. The one material legal proceeding is the Tiehm's buckwheat ESA appeal (Ninth Circuit, decision expected mid-2027) — an existential-tail risk, not an accounting one."

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (developer → milestone-and-value path, not EPS)

EPS projection is not meaningful — ioneer will report small losses every year until first production (~2029), then a step-change. The honest forward model is a probability-weighted path to value, with every input labeled. No forecast.ts EPS line is logged (per --watchlist rules, and because EPS is the wrong metric for a pre-revenue developer).

The economics, if built (Years 1–25 steady state):

• Revenue (illustrative): 24,500 t LCE × ~$19,000/t ≈ US$466M lithium + 135,500 t boric acid × ~$1,250/t ≈ US$169M boron ≈ ~US$635M/yr revenue. Cross-checks against management's stated ~US$563M average annual EBITDA (Yrs 1–25) at a high EBITDA margin — consistent with the low-cost / boron-credit claim.
• After-tax NPV₈ ~US$2,300M, IRR 23.2%.

Probability-weighted equity value:

• Bear (~40%): financing fails or drags / lithium stays weak / appeal succeeds. Equity gap not closed by 2027 runway; further dilution or impairment of the US$209M asset. Value: US$0.10–0.20B (option decays). Downside −50%+.
• Base (~45%): consortium signs binding in 2H-2026, FID taken, DOE draws. Re-rate toward a fraction of NPV as a financed, building developer — call it 0.25–0.35× NPV ≈ US$0.6–0.8B equity, but net of the equity ioneer must sell (a strategic partner buying ~50% of the project, plus continued corporate dilution, means existing holders own less of a larger, de-risked pie). Net per-share upside is real but muted by the dilution that funds it — roughly +50–100% on the equity, less per share.
• Bull (~15%): consortium signs on good terms + lithium price rallies into FID + appeal dismissed. Re-rate toward LAC-style ~US$1.4B+ as a financed, partner-backed, rising-lithium developer. +200–300%.

The asymmetry is genuinely interesting only because the asset is permitted and the NPV dwarfs the market cap — but the path is binary and dilutive. This is a position-sizing problem, not a conviction problem.

Brier-scoreable forecast (the one that actually matters for a developer): "ioneer signs a binding strategic-partner/consortium agreement (the DOE-loan equity condition precedent) by 2026-12-31" — p ≈ 0.45. (Not logged via forecast.ts per watchlist rules; flagged here for a future /thesis pass.)

Lens 12 · Bull vs Bear

Bull case. A fully-permitted, 100%-owned, only-of-its-kind US lithium-boron orebody with a ~$2.3B after-tax NPV and a 77-year life, trading at ~0.15× P/NAV and ~$0.36B market cap. The boron co-product is a structural, durable low-cost moat that lets it survive trough lithium prices. ~59% of capex is covered by a closed US$996M DOE loan; demand is ~90% offtaken (Ford, Toyota/Panasonic, EcoPro). The chairman built Orocobre — a lithium-plus-boron developer — into an ASX-300 producer once already. The missing piece is one equity partner, and a Korean consortium (KIND/Hyundai) is now at LOI. If lithium prices keep recovering (2026 spot already up ~80%+ off the trough, deficits projected 2027–28 ) into a 2H-2026 FID, this re-rates hard. Contrarian view the market refuses to see: the market is treating ioneer as a lithium price bet (and discounting it like a lottery ticket), when the boron credit makes it one of the few developers whose economics work regardless of where lithium settles — it is mis-bucketed as a pure-play lithium developer when it is really a low-cost boron+lithium chemicals project.

Bear case (2–3 permanent-impairment risks).

1. Financing failure / terminal dilution. The equity gap (~$687M+) has already claimed one partner (Sibanye, Feb-2025). If the consortium doesn't sign binding terms, ioneer either dilutes existing holders toward irrelevance or the project stalls and the US$209M E&E asset is impaired. Runway ends Apr-2027.
2. The Ninth Circuit appeal. A reversal on the Tiehm's-buckwheat ESA grounds could vacate the permit — the one thing that makes the asset valuable. Tail risk, but existential (decision ~mid-2027, after the planned FID — so FID may be taken with the appeal unresolved).
3. Capex inflation + execution. Capex already doubled (US$785M → US$1,683.2M) and management warns of more; a single-asset junior has no margin for an overrun, and first production is still ~2029 — a long fuse during which anything can break.

Pre-mortem (18 months out, thesis broke): Most likely story — the consortium LOIs never convert to binding equity on acceptable terms (or convert but on terms so dilutive existing holders barely participate in the upside); lithium prices soften again; the stock has been diluted through another raise to extend runway; and the Ninth Circuit overhang keeps a discount on the name. The asset is still "great" and still un-built.

Are multiples too high? No — at ~0.15× P/NAV the equity is cheap on the asset and expensive on the risk. The discount is rational, not a mispricing to fade blindly.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull: The bull case is an asset story attached to a financing problem the company has not solved in nine years of trying. Structurally, here's what breaks it:

• The whole equity is a financing option, and the option-writer keeps printing more options. Share count +13% in one quarter (Feb-2026 raise); contributed equity US$309M to build a US$209M asset. Every quarter without a binding partner is another raise. You are short the dilution, full stop.
• "Fully permitted" is not "fully litigated." The Ninth Circuit can take the permit. Bulls treat the District Court win as final — it isn't, and the appeal resolves after the FID window, so the company may commit ~US$1.7B with the permit still contestable.
• Sibanye already did the diligence and walked. The most informed potential partner — a mining company that put US$70M in and signed for 50% — reviewed updated studies and concluded the economics "did not meet … prudent pricing" hurdles. That is the single most damning data point: a strategic insider voted no. The Korean LOIs are non-binding and the next step (MOUs) is itself non-binding.
• Concentration: one asset, one country, two commodities, with ~90% of early lithium offtake to three counterparties (Ford, PPES, EcoPro) — if any renegotiate at FID (offtakes signed at 2021–22 price expectations), the economics shift.
• The boron credit is the moat — and boron pricing/volume is opaque. The 25%-of-revenue boron credit assumes ioneer can place ~135,500 tpa boric acid into a 4.5 Mtpa market dominated 85% by Eti Maden + Rio Tinto. If incumbents defend share on price, the credit that makes the lithium "low-cost" compresses.
• Capital allocation: management's incentive (5.7% ownership, comp tied to keeping the project alive) is to fund-and-build at almost any dilution, not to maximise per-share value. A clean alternative — sell the whole asset to a major and return cash — is not the path a developer team pursues.

What must hold for today's price: lithium prices stay firm-to-rising, a binding consortium closes in ~2H-2026 on non-catastrophic dilution, the Ninth Circuit affirms, and capex doesn't blow out again. If growth/economics disappoint 20–30% (lower lithium, higher capex), the NPV that justifies the equity compresses sharply and the financing gap widens. Single scenario that permanently impairs: Ninth Circuit vacates the permit — the US$209M asset and the entire thesis evaporate; plausibility is non-trivial given the entire known population of an ESA-listed species sits in the footprint.

Lens 14 · Management Questions (ordered by information value)

1. The Korean LOIs (KIND/Hyundai) are non-binding — what are the specific terms and percentage of project equity under discussion, and what is the realistic date for a binding agreement that satisfies the DOE condition precedent?
2. After Sibanye's exit, exactly how large is the equity cheque you need (US$ at the current US$1,683.2M capex), and how much further corporate dilution beyond a project-level partner sale should existing shareholders expect before first production?
3. Sibanye reviewed updated studies and concluded the economics didn't meet "prudent pricing" hurdles. What changed in the October 2025 technical report that a strategic partner would now underwrite that Sibanye would not?
4. What lithium and boric-acid price assumptions underpin the US$2.3B NPV / 23.2% IRR, and what do the economics look like at strip/contract prices a partner would actually use?
5. If the Ninth Circuit rules against the BLM/USFWS approval, what is the contingency — is there a project at all, and what happens to the DOE loan and the US$209M capitalised asset?
6. The boron credit is ~25% of revenue and the crux of the cost advantage. How firm are the boric-acid offtakes/volumes beyond the first four years, and how do you place 135,500 tpa against Eti Maden and Rio Tinto?
7. Capex doubled from US$785M to US$1,683.2M. What is your confidence interval on the next (pre-FID) estimate, and what reserve do you hold for overruns given you have one asset?
8. The runway extends to April 2027. What is the funding plan if a binding partner slips beyond 2H-2026?
9. The three anchor lithium offtakes (Ford, PPES, EcoPro) were signed in 2021–22. Are pricing mechanisms fixed, indexed, or open to renegotiation at FID, and is there counterparty-concentration risk?
10. What is the first-production date you would commit to at FID, and what is the critical path (acid plant, power, water) most likely to slip?
11. Given insider ownership is ~5.7%, how is management compensation aligned with per-share value rather than simply advancing the project / raising capital?
12. What role, if any, would the DOE loan's Treasury-linked rate and 20-year term play under different rate environments, and are there policy/political risks to ATVM funding under the current administration?
13. Is outright sale of the asset to a major (versus self-build) on the table, and how do you weigh that against the dilution path?
14. What is the plan and capital requirement for the Stage 2 / Lithium Clay R&D project currently excluded from economics — upside optionality or a future capital sink?
15. What hydrology/water-rights or reagent (sulphur/acid) supply risks remain unresolved that could affect the operating-cost assumptions underpinning the low-cost claim?

---